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ABSTRACT
PURPOSE: To evaluate telomerase activity and proliferation of HS839.T melanoma cells, subjected to the action of AZT. 
METHODS: Cells were grown in triplicate, AZT at different concentrations: 50, 100 and 200μM, was added and left for 24 and 48 
hours, and its effects were compared with the control group. Telomerase activity was detected by PCR and cell proliferation was 
evaluated by MTT. 
RESULTS: After 24 hours, there was no inhibition of cell proliferation or telomerase activity when compared to the control group. After 
48 hours, there was a momentary decrease, suggesting that the cell lines used in this study are sensitive to AZT, but quickly recover both 
the enzyme activity and cell proliferation. 
CONCLUSION: The action of AZT on the melanoma cells studied, at the concentrations and times tested, did not inhibit telomerase 
activity nor affect cell proliferation.
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RESUMO
OBJETIVO: Avaliar a atividade da telomerase e da proliferação de células de melanoma HS839.T submetidas à ação do AZT. 
MÉTODOS: As células foram cultivadas, em triplicata, com diferentes concentrações de AZT: 50, 100 e 200µM, por 24h e 48h, seus 
efeitos comparados com o grupo controle. A atividade da telomerase foi detectada por PCR e a proliferação celular avaliada por MTT. 
RESULTADOS: No tempo de 24 horas, não houve inibição da proliferação celular e da atividade da telomerase em comparação com 
o grupo controle. No período de 48 horas, houve uma diminuição momentânea, sugerindo que as células das linhagens utilizadas neste 
estudo são sensíveis ao AZT, mas que recuperam a atividade enzimática e proliferativa. 
CONCLUSÃO: Nas células de melanoma HS839.T estudadas e nas concentrações e tempos propostos, a ação do AZT não inibiu a 
atividade da telomerase e não afetou a proliferação celular. 
Descritores: Telomerase. Melanoma. Zidovudina. Proliferação de Células. In Vitro. 
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Introduction 
Melanoma results from the uncontrolled proliferation of 
melanoblasts, of unknown etiology, and is one of the tumour with 
poorest prognosis. Several factors contribute to its arising, such as 
a genetic predisposition, exposure to sunlight, physical traumas 
to pre-existent nevi and immunodeficiencies. Melanoma accounts 
for 3 to 4% of all malignant skin tumour1-4. Reports from various 
parts of the world have demonstrated an increase in its incidence 
and mortality rates5,6. 
Cancer cells present alterations in their nuclei, which 
usually occur in a single somatic cell that continues to divide 
until it forms a tumor. Its growth is fostered, among others, by 
angiogenic factors secreted by these cells, affecting even the 
maintenance of the DNA telomere size7-9.   
Telomeres are specialized structures located at the ends of 
eukaryotic chromosomes, constituted of complex nucleoproteins 
and essential for the stability of the genome10,11. Any telomere 
dysfunction contributes to reduce cell viability, altering the 
differentiation process12,13.   
The enzyme responsible for telomere synthesis is known 
as telomerase. It protects the ends of the DNA molecule against 
enzymatic degradation, preventing the occurrence of extremity 
fusions and warranting a correct duplication of the terminal 
regions of chromosomes, which may be necessary for the indefinite 
proliferation of human cells11,14.
Telomerase activity is absent in the majority of human 
somatic cells but present in immortalized cell lines, stem and 
germ cells and in approximately 90% of human cancers15. There 
are studies suggesting that the progression of malignant diseases 
depends on telomerase reactivation, and that an inhibiting agent of 
this enzyme could be an effective antitumor drug7,15. 
Azidothymidine triphosphate (AZT) was shown in vitro 
to inhibit the action of telomerase in several tumour, with an 
important reduction of the telomeric terminals10,16-19.  
The present study evaluated the telomerase activity and 
cell proliferation in HS839.T melanoma cells submitted to the 
action of AZT.  
Methods
Cell lines and cultures 
This study was approved by the Research Ethics 
Committee of Federal University of Sao Paulo under number 
156/07.
An immortalized isolated melanoma cell line named 
HS 839.T, catalog # CRL-7572, derived from skin with fibroblast 
morphology of a 42-year-old Caucasian female patient, was 
purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). The cells were kept in DMEM medium 
(Gibco, Grand Island, NY, USA), supplemented with 10% of FBS 
(Gibco, Grand Island, NY, USA), 0.02ml L-glutamine (Sigma 
Aldrich, St Louis, MO, USA), 4.5g/L glucose (Merck, New Jersey, 
USA), and 1.5g/L sodium bicarbonate (Merck, New Jersey, USA), 
and placed in an incubator at 37°C with 5% CO2. 
Treatment of cells
After achieving 80% flask confluence, the cells were 
trypsinized (0.01%) (Sigma Aldrich, St Louis, MO, USA) and 
submitted to different AZT concentrations, with one control 
group without drug addition, followed by a group to which 50µM, 
100µM and 200µM were added for 24 and 48 hours, respectively. 
The experiments were carried out in triplicate.
Cell viability 
MTT solution
In order to determine the metabolic activity and the 
degree of cell proliferation, 104 cells/well were distributed onto 
96-well microplates with 100µL of DMEM medium, with the 
same supplementation. The plates were kept at 37°C with 5% CO2 
for 24 hours. Then the medium was aspired and replaced by fresh 
supplemented DMEM medium, simultaneously adding AZT at the 
defined concentrations for 24 and 48 hours, respectively. 
The cells were incubated again at 37ºC for 24 and 48 
hours, respectively, then 10µl of MTT solution (5mg/ml) were 
added to each well, maintained for three hours, and then the 
medium was aspired and 100µl acidified isopropanol were added 
to each well for ten minutes, to dissolve the formazan crystals. 
Analysis was performed with an ELISA plate reader (Labsystem 
Multiskan EX, Helsinki, Finland) at a wavelength of 450nm, 
with a reference filter of 590nm, and the metabolic activity was 
obtained by using its percentage in relation to the control. 
Telomerase activity 
Cell preparation for telomerase analysis 
Cell preparation, reaction mixtures, PCR amplification 
and telomerase enzymatic expression analysis were performed 
with the Telomerase PCR ELISA® kit (Roche, Mannheim, 
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Germany) and the TRAPEZE® RT kit (Chemicon, Temecula, CA, 
USA), according to the manufacturers’ instructions.
Cells were trypsinized and the pellet was washed 
with a PBS solution (Sigma Aldrich, St Louis, MO, USA) and 
resuspended in 200µL CHAPS Lysis Buffer. The same procedure 
was performed with the TRAPEZE® RT kit, the cells were kept on 
ice for 30 minutes and then stored in a freezer at -80°C.
Telomerase PCR ELISA® kit 
The cell extracts were unfrozen and aliquots were analyzed 
by the immunoenzymatic method (hybridization and ELISA), 
using the Telomerase PCR ELISA® kit. The immunoabsorbance of 
the samples was measured with an ELISA plate reader (Labsystem 
Multiskan EX, Helsinki, Finland) at a450 nm wavelength, with 
a 690 nm reference filter. A sample was considered positive for 
telomerase enzymatic activity if its immunoabsorbance was higher 
than 0.2 A450nm–A690nm units. 
TRAPEZE® RT kit 
Preparation of reaction mixtures 
Aliquots of: 0.4μL Hot Start Taq Polymerase, 37.6 μL 
dH2O and 10-750 ng/μL cell extract were prepared with reagents 
supplied by the manufacturer (Chemicon, Temecula, CA, USA). 
The cell extracts were unfrozen and analyzed using the TRAPEZE® 
RT kit.
The reaction mixture was then placed in an Eppendorf 
tube and taken to the thermocycler (Corbett Research Rotor 
Gene 3000, Sidney, Australia) for extension and amplification 
by polymerase chain reaction (PCR). Once the reaction was 
completed, the telomerase enzymatic expression was analyzed 
using real-time PCR. 
To perform these experiments, a curve was constructed 
with standard protein (Figure 1), using 99% BSA (fraction V) 
(Sigma Aldrich, St Louis, MO, USA) and a protein assay kit 
(Biorad Laboratories, Hercules, CA, USA). 
FIGURE 1 - Standard curve: X axis - log [10] concentration of the protein 
extract sample; Y axis - Threshold Cycle (CT) values of the dilution 
points; on the line, the marked CT values. 
Results
Cell viability 
MTT solution
The results obtained for the enzymatic activity values in 
the cells of the 24-hours’ treatment group are presented in Figure 
2. A gradual increase of the cell population was observed in all 
groups during the 24-hour period compared to the control group, 
with a tendency towards a decrease in enzymatic activity when 
200µM of AZT were added.
FIGURE 2 - Treatment for 24 hours: positive control and AZT 
concentrations in µM, detection of cell viability by MTT, cell line 
HS839.T.
The results obtained for the enzymatic activity values in 
the cells of the 48-hours’ treatment group are presented in Figure 
3. A gradual increase of the cell population was observed in all 
groups during the 48-hour period compared to the control group, 
with no tendency towards a decrease in enzymatic activity when 
200µM of AZT were added. 
FIGURE 3 - Treatment for 48 hours: positive control and AZT 
concentrations in µM, detection of cell viability by MTT, cell line 
HS839.T.
Telomerase activity 
Telomerase PCR ELISA® kit 
 Telomerase activity was evaluated using the Telomerase 
PCR ELISA® kit in the control group and in the groups treated 
with AZT. The distribution of the immunoabsorbance values (OD) 
is shown in Figure 4. A gradual increase in telomerase activity was 
observed in all groups during the 24-hour period compared to the 
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control group, with a tendency towards a decrease in enzymatic 
activity when 200µM of AZT were added. 
FIGURE 4 - Treatment for 24 hours: positive control and AZT 
concentrations in µM, detection of specific telomerase activity in an 
HS839.T cell line by PCR-ELISA®. 
Telomerase activity was evaluated with the Telomerase 
PCR-ELISA kit, both in the control and in the groups treated with 
AZT. The distribution of the immunoabsorbance (OD) values 
concerning telomerase activity is presented in Figure 5. An initial 
decrease in telomerase activity was observed in the groups to 
which 50μM and 100μM of AZT had been added, after which 
there was a gradual increase compared to the control group, and 
no tendency towards a decrease in enzymatic activity was found 
with 200μM of AZT. 
FIGURE 5 - Treatment for 48 hours: positive control and AZT 
concentrations in µM, detection of specific telomerase activity in an 
HS839.T cell line by PCR-ELISA®. 
TRAPEZE® RT kit
Real-time polymerase chain reaction (RT-PCR) was 
performed using a TRAPEZE® RT kit, both in the control and in 
the groups treated with AZT (Figures 6 and 7). A gradual increase 
in telomerase enzymatic activity was observed in all groups 
treated for 24 hours compared to the control group, and a tendency 
towards a decrease in enzymatic activity was found with 200μM 
of AZT. 
FIGURE 6 - Treatment for 24 hours: positive control and AZT 
concentrations in µM, specific detection of telomerase activity in an 
HS839.T cell line by TRAPEZE RT®.
FIGURE 7 - Quantification of 24-hour samples, number of cycles: 
fluorescence monitoring curve illustrating real-time amplification.
RT-PCR was performed using a TRAPEZE® RT kit, both 
in the control and in the groups treated with AZT (Figures 8 and 
9). 
FIGURE 8 - Treatment for 48 hours: positive control and AZT 
concentrations inµM, specific detection of telomerase activity in an 
HS839.T cell line by TRAPEZE RT®.
FIGURE 9 - Quantification of 48-hour samples, number of cycles: 
fluorescence monitoring curve illustrating real-time amplification. 
A gradual increase in telomerase enzymatic activity was 
observed in all groups treated for 48 hours compared to the control 
group, and no tendency towards a decrease in enzymatic activity 
was found with 200μM of AZT. 
To analyze the data resulting from this combination of 
distinct methodologies, we chose triangulation. The use of different 
data collection methods and the comparison of the results, i. e., 
the convergence or corroboration of the information gathered and 
interpreted concerning the same phenomenon, considering that 
validity and reliability are measures of consistency20. The data 
resulting from the experiments were compared and correlated with 
each other, in order to point out patterns, themes and concepts21, 
thus organizing basic descriptive units and interpretations 
involving the attribution of a meaning to the analyses, explaining 
the patterns found and searching for relationships among the 
descriptive dimensions. 
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The primary theoretical reference in this study was 
qualitative, due to the fact that the sample was typically small, 
since we were looking for a cell behavior in front of a single bias, 
the different concentrations of AZT22. 
Discussion 
Melanoma develops from a malignant transformation 
of melanocytes, which undergo an uncontrolled growth and 
alterations in the nucleus20,21. 
There is strong evidence indicating an association 
between the maintenance of telomeres and the development of most 
of the various types of cancer in humans, including melanoma22.
Telomerase functions as a reverse transcriptase and its 
inhibiting agents are being tested, among them azidothymidine 
triphosphate, zidovudine (AZT), and it has been proven that in 
vitro this drug inhibits the action of telomerase10,16,17-19,23.
The objective of the present study was to evaluate the 
activity of telomerase and the proliferation of immortalized 
HS839.T melanoma cells submitted to the action of AZT, using 
MTT, the Telomerase PCR Elisa Kit and the telomerase Trapeze 
RT Kit.
For this purpose, we chose the melanoma cell line HS 
839.T, in which this enzyme is active, because the behavior of this 
cell line is predictable and homogeneous. 
To analyze the data resulting from this combination of 
distinct methodologies, we chose triangulation. The use of different 
data collection methods and the comparison of the results, i. e., 
the convergence or corroboration of the information gathered and 
interpreted concerning the same phenomenon, considering that 
validity and reliability are measures of consistency24. The data 
resulting from the experiments were compared and correlated with 
each other, in order to point out patterns, themes and concepts25, 
thus organizing basic descriptive units and interpretations 
involving the attribution of a meaning to the analyses, explaining 
the patterns found and searching for relationships among the 
descriptive dimensions.   
The primary theoretical reference in this study was 
qualitative, due to the fact that the sample was typically small, 
since we were looking for a cell behavior in front of a single bias, 
the different concentrations of AZT26. 
The evaluation of cell viability was performed according 
to the MTT technique27.
The AZT concentrations used were those most frequently 
mentioned in the literature10,16-18, and we added them directly to the 
culture medium, respecting the 24 and 48-hours’ time of action. 
All the experiments were carried out in triplicate because this is 
the ideal in vitro study design, once cells of the same cell line carry 
the same genetic material, ruling out any other bias. 
The tests showed a gradual increase of the cell population 
in all groups treated with AZT for 24 hours compared to the control 
groups, with a tendency to decrease at the 200µM concentration. 
In the 48-hour groups, the same pattern was observed, but without 
the tendency to decrease at the dosage of 200µM.
Telomerase activity was evaluated in the cell groups 
treated with AZT for 24 and 48 hours and in the control groups, 
using the Telomerase PCR Elisa Kit, according to a previously 
described methodology7. 
Telomerase activity was also measured using the 
commercial Trapeze® RT kit, because it allows real-time detection 
of the enzyme telomerase after fragment amplification in a 
thermocycler.
The results obtained with the 24-hours’ treatment suggest 
that none of the different AZT concentrations (50µM, 100µM, 
and 200µM) inhibited the telomerase activity as compared to the 
control group, although they suggest a tendency to a decrease with 
200µM.
Analyzing the results of the 48-hours’ treatment, the 
same pattern was found, with an indication of a slight decrease 
in telomerase activity at the concentration of 50µM compared to 
the control group, although it was followed by a gradual increase 
in the activity of this enzyme, possibly related to the fact that the 
concentrations should have been higher, as suggested by Humer 
et al.28. Actually, our data corroborate the findings of Humer et 
al.28, who studied growth inhibition of melanoma cells in vivo and 
in vitro and observed that AZT concentrations below 200µM did 
not produce measurable cytotoxic effects on the cells, but with 
higher concentrations up to 500µM and a longer exposure time 
up to 72hours, the tested cells showed a substantial increase in 
apoptosis, indicating a dose-dependent relationship. These data 
suggest that the HS839.T melanoma cells used in the present study 
are sensitive to AZT, but regain their enzymatic and proliferation 
activity, with a possible neutralization of the reverse transcriptase 
inhibiting nucleoside originated from AZT.
In conclusion, the action of AZT in HS839.T melanoma 
cells at the concentrations and time periods tested did not inhibit 
telomerase activity, nor did it affect cell proliferation. However, 
based on our results and on the findings of Humer et al.28, we 
will conduct further experiments, performed with melanoma cells 
obtained by fine-needle aspiration puncture (FNAP), submitted to 
AZT treatment starting from 200 µM and with increasing doses 
and exposure of these cells to the drug for a period of time longer 
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than 48 hours. 
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